BD (NYSE:BDX) today announced the first pharma-sponsored combination product clinical trial using its wearable injector technology.

Becton Dickinson (BDX) recently announced the initiation of a pharma-sponsored clinical trial featuring their BD Libertas Wearable Injector, alongside an affirmed quarterly dividend and leadership ...

In a positive wrinkle, the makers of Tokyo Beast will compensate NFT owners and some TGT token holders amid the game’s ...

Ethereum is likely to head higher as demand for ETH outpaces the supply, an analyst from ETF issuer Bitwise wrote in a recent ...

Key Points Medtronic is closing in on Dividend King status and has a historically high yield.Becton, Dickinson is already a Dividend King and has a relatively high yield.Universal Health has a huge ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” second quarter 2025 investor ...

Becton Dickinson (BDX) announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for ...